AbbVie launches multi-tranche debt offering to fund $10.9B Apogee acquisition
ABBV sits 30% above its 52-week low of $189.785.
Summary
AbbVie is issuing senior notes across nine tranches to fund its pending $10.9 billion acquisition of Apogee Therapeutics. The offering includes a special mandatory redemption feature that protects bondholders if the acquisition is terminated. The offering was priced at $10.0 billion total principal with settlement expected August 18, 2026.
Updated with an SEC FWP filing · What changed
Updates
· SEC FWP — AbbVie priced the nine-tranche offering at $10.0 billion total principal: $500M floating rate notes due 2028 at SOFR+42bps, $1.0B 4.500% notes due 2028, $1.25B 4.650% notes due 2030, $1.5B 4.875% notes due 2031, $1.25B 5.050% notes due 2033, $1.5B 5.300% notes due 2036, $1.0B 5.450% notes due 2038, $1.5B 6.000% notes due 2056, and $500M 6.100% notes due 2066. Settlement is expected August 18, 2026.
Key Events · Financing and Capital Events · ABBV
-
Updated · · SEC FWP
Debt Offering Priced at $10.0 Billion
To fund a portion of its $10.9 billion acquisition of Apogee Therapeutics, AbbVie is offering nine tranches of senior notes, including floating rate and fixed rate notes. The offering was priced at $10.0 billion total principal: $500M floating rate notes due 2028 at SOFR+42bps, $1.0B 4.500% notes due 2028, $1.25B 4.650% notes due 2030, $1.5B 4.875% notes due 2031, $1.25B 5.050% notes due 2033, $1.5B 5.300% notes due 2036, $1.0B 5.450% notes due 2038, $1.5B 6.000% notes due 2056, and $500M 6.100% notes due 2066. Settlement is expected August 18, 2026.
-
Special Mandatory Redemption Feature
Seven of the nine tranches are subject to a special mandatory redemption at 101% of principal plus accrued interest if the Apogee acquisition agreement is terminated. The two long-term notes are not subject to this redemption.
-
Bridge Loan Reduction
The net proceeds from this offering will reduce commitments under AbbVie's $10.0 billion 364-Day Delayed Draw Term Loan Facility, which was established in July 2026 as bridge financing for the acquisition.
-
Use of Proceeds
Proceeds will be used to fund the Apogee acquisition and for general corporate purposes, which may include repaying or repurchasing outstanding debt.
Analysis · ABBV · Life Sciences
To finance its $10.9 billion acquisition of Apogee Therapeutics, AbbVie is tapping the bond market with a multi-tranche senior notes offering. A special mandatory redemption feature on seven of the nine tranches protects investors—if the Apogee deal falls through, those notes must be redeemed at 101% of principal. This structure signals AbbVie's commitment to closing the acquisition. The offering will reduce commitments under a $10 billion bridge loan, replacing short-term bank debt with longer-term bond financing. The nine tranches were priced at $10.0 billion total principal, with settlement expected August 18, 2026. For a company of AbbVie's size, this is a routine capital markets execution, but the size and the acquisition context make it a notable event.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABBV was trading at $247.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $433B. The 52-week trading range was $189.79 to $267.47. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.